Riik: Malta
keel: inglise
Allikas: Medicines Authority
VALPROATE SODIUM
Sanofi Malta Limited
N03AG01
VALPROATE SODIUM
ORAL SOLUTION
VALPROATE SODIUM 200 mg/5ml
POM
ANTIEPILEPTICS
Authorised
2008-07-01
1 301968 - 968 PACKAGE LEAFLET: INFORMATION FOR THE USER EPILIM 200MG/5ML LIQUID sodium valproate IS THIS LEAFL ET HARD TO SEE OR READ? PHONE 0845 372 7101 FOR HELP ▼ This medicine is subject to additional monitoring. This will allow quick identifi cation of new safety information. You can help by reporting any side eff ects you may get. See the end of section 4 for how to report side eff ects. WARNING Valproate can cause birth defects and problems with early development of the child if it is taken during pregnancy. If you are a female of childbearing age you should use an eff ective method of contraception throughout your treatment. Your doctor will discuss this with you but you should also follow the advice in section 2 of this leafl et. Tell your doctor at once if you become pregnant or think you might be pregnant. READ ALL OF THIS LEAFL ET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leafl et. You may need to read it again • If you have further questions, please ask your doctor or pharmacist • This medicine has been prescribed for you. Do not pass it on to others. It may harm them even if their symptoms are the same as yours • If you get any side eff ects, talk to your doctor or pharmacist. This includes any possible side eff ects not listed in this leafl et. See section 4. WHAT IS IN THIS LEAFL ET 1. What Epilim Liquid is and what it is used for 2. What you need to know before you take Epilim Liquid 3. How to take Epilim Liquid 4. Possible side eff ects 5. How to store Epilim Liquid 6. Contents of the pack and other information 1. WHAT EPILIM LIQUID IS AND WHAT IT IS USED FOR WHAT EPILIM LIQUID IS The name of your medicine is Epilim 200mg/5ml Liquid (called Epilim Liquid in this leafl et). WHAT EPILIM LIQUID CONTAINS Epilim Liquid contains a medicine called sodium valproate. This belongs to a group of medicines call Lugege kogu dokumenti
Page 1 of 16 SUMMARY OF PRODUCT CHARACTERISTICS _▼_ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Epilim 200mg/5ml Liquid 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 5ml of liquid contains Sodium Valproate 200.0mg. 3. PHARMACEUTICAL FORM Liquid 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS In the treatment of generalised, partial or other epilepsy. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Epilim Liquid is for oral administration. Daily dosage requirements vary according to age and body weight. Epilim Liquid may be given twice daily. Epilim Liquid should not be diluted. In patients where adequate control has been achieved Epilim Chrono formulations are interchangeable with other conventional or prolonged release formulations on an equivalent daily dosage basis. _Dosage _ Usual requirements are as follows: Adults Dosage should start at 600mg daily increasing by 200mg at three-day intervals until control is achieved. This is generally within the dosage range 1000mg to 2000mg per day, ie 20- 30mg/kg/day body weight. Where adequate control is not achieved within this range the dose may be further increased to 2500mg per day. Children over 20kg Initial dosage should be 400mg/day (irrespective of weight) with spaced increases until control is achieved; this is usually within the range 20-30mg/kg body weight per day. Where adequate control is not achieved within this range the dose may be increased to 35mg/kg body weight per day. Page 2 of 16 Children under 20kg 20mg/kg of body weight per day; in severe cases this may be increased but only in patients in whom plasma valproic acid levels can be monitored. Above 40mg/kg/day, clinical chemistry and haematological parameters should be monitored. Use in the elderly Although the pharmacokinetics of Epilim are modified in the Lugege kogu dokumenti